AMETEK arrives at mid-August in a quietly constructive position — a stock that just posted a well-received quarter, collected a round of analyst target upgrades, and continues to attract almost no meaningful bearish conviction from short sellers.
The most interesting development this week is on the Street. Post-Q2 earnings on August 4, multiple analysts moved their targets higher in unison. Truist raised its target to $316 and kept its Buy rating. RBC and Keybanc each pushed targets up to $291 and $295 respectively. DA Davidson and BNP Paribas also lifted targets, all while maintaining positive ratings. The sole exception to the bullish tilt is Citigroup, which holds a Neutral and bumped its target only marginally to $261 — roughly in line with the current price of $254.79. Morgan Stanley sits at Equal-Weight with a $245 target, the only house effectively flagging downside from here. Consensus sits at a mean target of $277, implying about 9% upside. The bull case rests on AMETEK's record in niche market dominance and acquisition-led compounding. Bears point to integration risk and the difficulty of sustaining above-average organic growth when macro conditions tighten.
The earnings print itself validated the bullish camp. The stock rose 4.5% on August 4 and added another 0.6% over the following five days — a clean post-earnings expansion that has carried the stock up 8.9% over the past month. The options market reflects this more relaxed tone. The put/call ratio has drifted down to 0.42, modestly above its 20-day average of 0.37 but well below the defensive readings of 0.58–0.67 that characterised mid-July. That earlier cluster of put-buying, which coincided with pre-earnings uncertainty, has unwound almost entirely. The z-score of 0.8 places current positioning just inside normal territory — call buyers are no longer reluctantly hedging.
Short interest has nothing interesting to say here, and that itself is notable. Bears have trimmed positions by roughly 10% over the past month, with SI at just 1.36% of the free float. Borrow is abundant — availability is effectively uncapped relative to short positions outstanding — and cost to borrow, though it jumped to 0.47% this week from a recent low near 0.18%, remains trivially cheap in absolute terms. The uptick in borrowing cost is almost certainly noise rather than signal given the scale. The ORTEX short score of 30.7 has barely moved across the past two weeks, confirming the lending market is not a driver of price action in either direction.
One insider move worth registering: director Nick Stanage bought 4,000 shares on August 11 at $255.85, a $1 million-plus purchase made after the earnings pop rather than ahead of it. That timing — buying into a freshly elevated price — reads as directional conviction rather than a pre-event hedge. It is a small percentage of the company but large enough to clear materiality thresholds. Contrast it with a division president selling $1.7 million of stock on August 7, which looks more like routine compensation monetisation. The net insider position over 90 days is modestly positive.
Institutional ownership is stable and concentrated in the usual passive and active giants. BlackRock reported adding 705,000 shares through July, making it the largest holder at 8.5% of shares. Wellington and Norges Bank both added meaningfully in the prior quarter. There is no sign of a large active manager exiting. With the next earnings date on October 30, the near-term watch will be whether the multiple — currently a P/E of 29.3 and EV/EBITDA of 22.3 — can hold at these levels as the broader industrial cycle data rolls in, or whether AMETEK's quality premium faces a compression test alongside peers like EMR, which gained 3.1% on the week, and ETN, which was roughly flat.
See the live data behind this article on ORTEX.
Open AME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
